Literature DB >> 15389473

Contralateral prophylactic mastectomy. Predictors of significant histologic findings.

Katja Goldflam1, Kelly K Hunt, Jeffrey E Gershenwald, S Eva Singletary, Nadeem Mirza, Henry M Kuerer, Gildy V Babiera, Frederick C Ames, Merrick I Ross, Barry W Feig, Aysegul A Sahin, Banu Arun, Funda Meric-Bernstam.   

Abstract

BACKGROUND: Women with unilateral breast carcinoma are at increased risk for developing contralateral breast carcinoma (CBC). The authors sought to identify predictors of malignant or moderate to high-risk histologic findings in contralateral prophylactic mastectomy (CPM) specimens, and to determine the efficacy of CPM.
METHODS: The authors performed a retrospective review of 239 patients with unilateral early-stage breast carcinoma who underwent CPM. The number of CBCs expected if the contralateral breast had been left intact was calculated based on CBC rates observed in the Surveillance, Epidemiology, and End Results (SEER) database and on life-table analysis by family history.
RESULTS: In the current study, 11 patients (4.6%) had occult contralateral malignancies (4 invasive carcinomas and 7 ductal carcinomas in situ) and 44 (18.4%) patients had moderate to high-risk pathology (8 lobular carcinoma in situ, 11 atypical lobular hyperplasia, 25 atypical ductal hyperplasia). At 1846 patient-years of follow-up, only 1 patient (0.4%) developed a new CBC compared with 11 expected cancers based on SEER data. One CBC was observed among 140 patients with a family history of breast carcinoma, compared with 16 expected cancers based on life-table analysis adjusted for adjuvant therapy. The determinants of significant findings at CPM were invasive lobular histology, estrogen and progesterone receptor positivity, additional ipsilateral moderate to high-risk pathology, and age > 40 years at cancer diagnosis.
CONCLUSIONS: CPM was associated with a low risk of subsequent development of breast carcinoma. Evaluation of histologic findings in the ipsilateral breast may help to predict the likelihood of significant disease in the contralateral breast and assist in risk stratification.

Entities:  

Mesh:

Year:  2004        PMID: 15389473     DOI: 10.1002/cncr.20617

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  22 in total

1.  Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy.

Authors:  Min Yi; Kelly K Hunt; Banu K Arun; Isabelle Bedrosian; Angelica Gutierrez Barrera; Kim-Anh Do; Henry M Kuerer; Gildy V Babiera; Elizabeth A Mittendorf; Kaylene Ready; Jennifer Litton; Funda Meric-Bernstam
Journal:  Cancer Prev Res (Phila)       Date:  2010-07-20

Review 2.  Contralateral prophylactic mastectomy after unilateral breast cancer: a systematic review and meta-analysis.

Authors:  Oluwadamilola Motunaryo Fayanju; Carolyn R T Stoll; Susan Fowler; Graham A Colditz; Julie A Margenthaler
Journal:  Ann Surg       Date:  2014-12       Impact factor: 12.969

Review 3.  The increasing use of prophylactic mastectomy in the prevention of breast cancer.

Authors:  Todd M Tuttle; Andrea Abbott; Amanda Arrington; Natasha Rueth
Journal:  Curr Oncol Rep       Date:  2010-01       Impact factor: 5.075

4.  Predictors that influence contralateral prophylactic mastectomy election among women with ductal carcinoma in situ who were evaluated for BRCA genetic testing.

Authors:  Nisreen Elsayegh; Henry M Kuerer; Heather Lin; Angelica M Gutierrez Barrera; Michelle Jackson; Kimberly I Muse; Jennifer K Litton; Constance Albarracin; Aimaz Afrough; Gabriel N Hortobagyi; Banu K Arun
Journal:  Ann Surg Oncol       Date:  2014-05-06       Impact factor: 5.344

5.  Contralateral prophylactic mastectomy is associated with a survival advantage in high-risk women with a personal history of breast cancer.

Authors:  Judy C Boughey; Tanya L Hoskin; Amy C Degnim; Thomas A Sellers; Joanne L Johnson; Melanie J Kasner; Lynn C Hartmann; Marlene H Frost
Journal:  Ann Surg Oncol       Date:  2010-09-19       Impact factor: 5.344

6.  Cost-effectiveness of contralateral prophylactic mastectomy versus routine surveillance in patients with unilateral breast cancer.

Authors:  Benjamin Zendejas; James P Moriarty; Jamie O'Byrne; Amy C Degnim; David R Farley; Judy C Boughey
Journal:  J Clin Oncol       Date:  2011-06-20       Impact factor: 44.544

7.  Predictors of contralateral breast cancer in patients with unilateral breast cancer undergoing contralateral prophylactic mastectomy.

Authors:  Min Yi; Funda Meric-Bernstam; Lavinia P Middleton; Banu K Arun; Isabelle Bedrosian; Gildy V Babiera; Rosa F Hwang; Henry M Kuerer; Wei Yang; Kelly K Hunt
Journal:  Cancer       Date:  2009-03-01       Impact factor: 6.860

8.  Gene expression in histologically normal epithelium from breast cancer patients and from cancer-free prophylactic mastectomy patients shares a similar profile.

Authors:  K Graham; A de las Morenas; A Tripathi; C King; M Kavanah; J Mendez; M Stone; J Slama; M Miller; G Antoine; H Willers; P Sebastiani; C L Rosenberg
Journal:  Br J Cancer       Date:  2010-03-02       Impact factor: 7.640

Review 9.  Genetic counselling and testing for inherited gene mutations in newly diagnosed patients with breast cancer: a review of the existing literature and a proposed research agenda.

Authors:  Bettina Meiser; Kathy Tucker; Michael Friedlander; Kristine Barlow-Stewart; Elizabeth Lobb; Christobel Saunders; Gillian Mitchell
Journal:  Breast Cancer Res       Date:  2008-11-28       Impact factor: 6.466

10.  Mastectomies on the rise for breast cancer: "the tide is changing".

Authors:  Charles M Balch; Lisa K Jacobs
Journal:  Ann Surg Oncol       Date:  2009-07-31       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.